Who to call at Moleculin Biotech, Inc., and when
Fundz watches for the moments Moleculin Biotech, Inc. starts buying, and tells you who to reach.
- An alert the day Moleculin Biotech, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Moleculin Biotech, Inc., from your own LinkedIn network
Moleculin Biotech, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
moleculin.comAI Executive Summary
AI-powered analysis of 8-K filing content
Moleculin Biotech announced promising preclinical data showing that its lead drug candidate Annamycin demonstrates antitumor activity in pancreatic cancer, partially mediated by CD8+ T cell cytotoxicity. This data presentation at a major oncology conference strengthens the company's competitive positioning in the oncology market.
Key Takeaways
Annamycin (naxtarubicin) shows antitumor activity in pancreatic cancer through CD8+ T cell-mediated cytotoxicity mechanism
Findings are being presented at the AACR Conference on Pancreatic Cancer (September 25-28, 2026) in San Diego, providing third-party validation
1 more takeaway
Filing Overview
What This Means
Moleculin Biotech, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.